Cargando…

Epoprostenol Exposure During Pregnancy

Institutional policies restricting pregnant providers from caring for patients receiving inhaled epoprostenol exist across the nation based on little to no data to substantiate this practice. Over the last 2 decades, the use of inhaled pulmonary vasodilators has expanded in patients with cardiac and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naoum, Emily E., LaVita, Carolyn, Lopez, Natasha, Nardone, Alexa, Soffer, Marti D., Shelton, Kenneth T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456979/ https://www.ncbi.nlm.nih.gov/pubmed/37637356 http://dx.doi.org/10.1097/CCE.0000000000000928

Ejemplares similares

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
por: Timofeev, Julia, et al.
Publicado: (2013)

Epoprostenol: Flushing or Erythroderma?
por: Martínez-Martínez, María Luisa, et al.
Publicado: (2013)

Epoprostenol: Exacerbation of thrombocytopenia : case report
Publicado: (2021)

Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol
por: Gionfriddo, William J., et al.
Publicado: (2020)

Epoprostenol‐associated ascites in pulmonary arterial hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2022)

HIGH-FLOW NASAL CANULA AND INHALED EPOPROSTENOL RESPONSE IN COVID-19
por: KHURANA, NEHARIKA, et al.
Publicado: (2022)

Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015)

Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
por: Mohammadi, Asma, et al.
Publicado: (2021)

Alteplase/epoprostenol: Lack of efficacy: case report
Publicado: (2022)

NATO Advanced Study Institute
por: LaVita, James A, et al.
Publicado: (1974)

Microbial challenge test of a novel epoprostenol sodium formulation
por: Bandilla, Dirk, et al.
Publicado: (2017)

Successful use of inhaled epoprostenol as rescue therapy for pediatric ARDS
por: Urich, Alissa, et al.
Publicado: (2020)

Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
por: Abughazaleh, Shaadi, et al.
Publicado: (2020)

Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19
por: Sonti, Rajiv, et al.
Publicado: (2020)

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
por: Sitbon, Olivier, et al.
Publicado: (2017)

Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19
por: Poonam, Pai B. H., et al.
Publicado: (2022)

PSAT054 Isolated ACTH Deficiency in a Patient on Epoprostenol
por: Riordan, Marianne, et al.
Publicado: (2022)

Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
por: Frantz, Robert P., et al.
Publicado: (2015)

Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
por: Calcaianu, George, et al.
Publicado: (2017)

Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension
por: Abston, Eric, et al.
Publicado: (2020)

Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
por: Guan, Zheng, et al.
Publicado: (2018)

Occult catheter rupture causing episodic symptoms in a patient treated with epoprostenol
por: LeVarge, Barbara L., et al.
Publicado: (2017)

The impact of nebulized epoprostenol and iloprost on hemoglobin oxygen affinity: an ex vivo experiment
por: Woyke, Simon, et al.
Publicado: (2022)

Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol
por: Izumi, Keiichi, et al.
Publicado: (2022)

Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension
por: Preston, Ioana R., et al.
Publicado: (2013)

In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients
por: Li, Jie, et al.
Publicado: (2021)

Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted
por: Lambert, Olivier, et al.
Publicado: (2012)

Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Lambert, Olivier, et al.
Publicado: (2012)

Epoprostenol discontinuation in patients with pulmonary arterial hypertension: a complex medical and social problem
por: Chebib, Nader, et al.
Publicado: (2017)

Refractory Cardiogenic Shock from Right Ventricular Infarction Successfully Managed with Inhaled Epoprostenol
por: Held, Natalie, et al.
Publicado: (2017)

Effects of Inhaled Epoprostenol and Prone Positioning in Intubated Coronavirus Disease 2019 Patients With Refractory Hypoxemia
por: Li, Jie, et al.
Publicado: (2020)

Timely care for extrauterine pregnancies during the COVID-19 pandemic is needed
por: la Cour Freiesleben, Nina, et al.
Publicado: (2021)

COMPARISON OF HIGHER VERSUS LOWER DOSE STEROID ADMINISTRATION IN PATIENTS WITH COVID-19 AND ACUTE HYPOXEMIC RESPIRATORY FAILURE ON INHALED EPOPROSTENOL
por: RIEGO, MARIA ATHENA, et al.
Publicado: (2022)

Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
por: Kimura, Mai, et al.
Publicado: (2015)

Cardiovascular Effect of Epoprostenol and Intravenous Cardiac Drugs for Acute Heart Failure on Canine Pulmonary Hypertension
por: Yuchi, Yunosuke, et al.
Publicado: (2023)

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
por: Alexandre, André, et al.
Publicado: (2023)

Protecting patients and staff in residential treatment centers during exposure to COVID-19: commentary
por: Johnson, Kimberly A., et al.
Publicado: (2021)

Anesthesia for Cesarean Delivery in a Patient with Congenitally Corrected Transposition of the Great Arteries: A Case Report
por: Naoum, Emily E., et al.
Publicado: (2023)

Health effects of non-occupational exposure to oil extraction
por: O’Callaghan-Gordo, Cristina, et al.
Publicado: (2016)

No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial
por: Kooter, Albertus J, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vu8h27tc1fapdt98rj33n89bao